Comparative Pharmacology
Head-to-head clinical analysis: CYTOVENE versus TPOXX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYTOVENE versus TPOXX.
CYTOVENE vs TPOXX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ganciclovir is a synthetic guanosine analog that inhibits viral DNA synthesis by competitively inhibiting viral DNA polymerase and by incorporation into viral DNA, causing chain termination. It is phosphorylated intracellularly to ganciclovir triphosphate, which is active against cytomegalovirus (CMV).
TPOXX (tecovirimat) inhibits the orthopoxvirus VP37 envelope protein, preventing viral egress from infected cells and reducing viral spread.
Induction: 5 mg/kg IV every 12 hours for 14-21 days; maintenance: 5 mg/kg IV once daily for 7 days per week or 6 mg/kg IV once daily for 5 days per week
600 mg orally twice daily for 14 days.
None Documented
None Documented
Terminal elimination half-life: 3-4 hours in normal renal function; prolonged to 28-40 hours in severe renal impairment (CrCl <10 mL/min)
Terminal half-life ~19 hours (range 10–48 h) in healthy adults; prolonged in renal impairment (up to ~100 h).
Primarily renal excretion as unchanged drug (>90%); 1-2% biliary/fecal
Fecal (primarily as unchanged drug, ~75%); renal (~25%, mostly as metabolites; <2% unchanged in urine).
Category C
Category C
Antiviral Agent
Antiviral Agent